Investigational drug · Phase 3
HSK31858
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
13
Any phase or sponsor naming "HSK31858"
First trial start
2024
Sep 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK31858", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-cystic Fibrosis Bronchiectasis
- Asthma Bronchiale
- Bronchiectasis
- Chronic Obstructive Pulmonary Disease (COPD)
Approved drugs for the same conditions: Asthma · COPD · Cystic fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK31858" as an intervention, largest first.
- A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07616375 · 669 participants (planned) · Start Sep 28, 2025 · Primary completion Jan 10, 2029
Drug: HSK31858, tablet · For: Non-cystic Fibrosis Bronchiectasis
Sites: Yixingcun, China
- A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06660992 · 669 participants (planned) · Start Sep 30, 2024 · Primary completion Nov 28, 2026
Drug: HSK31858, tablet; Placebo · For: Non-cystic Fibrosis Bronchiectasis
Sites: Guangzhou, China; Yixingcun, China
- A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus HypersecretionPivotal-lookingEnrolling by invitation
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06820749 · 309 participants (planned) · Start Dec 10, 2024 · Primary completion Apr 23, 2026
Drug: HSK31858; Placebo · For: Asthma Bronchiale; Bronchiectasis; Chronic Obstructive Pulmonary Disease (COPD)
Sites: Beijing, China
- A Study of HSK31858 in Participants with Non-Cystic Fibrosis BronchiectasisPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05601778 · 226 participants · Start Dec 6, 2022 · Primary completion Mar 29, 2024
Drug: HSK31858; placebo · For: Non-cystic Fibrosis Bronchiectasis (NCFBE)
Sites: Guangzhou, China
- A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial AsthmaPivotal-lookingStatus unknown
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06637254 · 219 participants (planned) · Start Oct 22, 2024 · Primary completion Mar 22, 2026
Drug: HSK31858; Placebo · For: Bronchial Asthma
Sites: Shanghai, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05663593 · 74 participants · Start Feb 23, 2022 · Primary completion Aug 15, 2022
Drug: HSK31858, tablet; Placebo, tablet · For: Healthy Volunteers
Sites: Zibo, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07915024 · 47 participants (planned) · Start Aug 6, 2026 · Primary completion Nov 2026
Drug: HSK31858 tablet; Placebo and 1 more · For: Non-cystic Fibrosis Bronchiectasis (NCFBE)
Sites: Jinan, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT05023525 · 32 participants · Start Oct 28, 2021 · Primary completion Apr 19, 2022
Drug: HSK31858, tablet; Placebo, tablet · For: Healthy
Sites: Melbourne, Australia
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07913009 · 30 participants (planned) · Start Mar 16, 2026 · Primary completion Dec 2026
Drug: HSK31858 tablets · For: Non-cystic Fibrosis Bronchiectasis (NCFBE)
Sites: Zhenzhou, China
- Clinical Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HSK31858 in Healthy SubjectsEnrolling by invitation
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07134465 · 24 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 30, 2026
Drug: HSK31858 Tablets and Itraconazole Capsules · For: Healthy Subjects
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Florensocatib in adults with bronchiectasis: the HOPE-BE trial protocol and baseline demographic characteristics.
Zhong NS, Cao J, Feng Y, et al. · ERJ Open Res 2026
- Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast.
Flume PA, Maselli DJ · Pulm Ther 2026
- Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects.
Zhang D, Zhang W, Hu P, et al. · Front Pharmacol 2025
- Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study.
Wang Y, Yu C, Hu M, et al. · Br J Clin Pharmacol 2025
- Dipeptidyl peptidase 1 inhibitors and neutrophilic inflammation in bronchiectasis: a narrative review.
Tang RD, Yue JQ, Chalmers JD, et al. · J Thorac Dis 2025
- Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
Zhong NS, Qiu R, Cao J, et al. · Lancet Respir Med 2025
Also in development for Non-cystic Fibrosis Bronchiectasis
- GalvokimigUCB9741Phase 23 trials
UCB · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis
- CSL787Phase 21 trial
CSL Behring · Non-cystic Fibrosis Bronchiectasis
- RESP302Phase 21 trial
Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis
- RESP303Phase 21 trial
Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.